Purity | Size | Price | VIP Price | USA Stock *0-1 Day | Global Stock *5-7 Days | Quantity | |||||
{[ item.p_purity ]} | {[ item.pr_size ]} |
{[ getRatePrice(item.pr_usd, 1,1) ]} {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]} |
{[ getRatePrice(item.pr_usd, 1,1) ]} | Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_usd,1,item.mem_rate) ]} | {[ item.pr_usastock ]} | Inquiry - | {[ item.pr_chinastock ]} | Inquiry - |
* Storage: {[proInfo.prStorage]}
CAS No. : | 74803-32-0 | MDL No. : | MFCD09834989 |
Formula : | C5H3ClN4 | Boiling Point : | - |
Linear Structure Formula : | - | InChI Key : | VZMFNXVRYOJRMK-UHFFFAOYSA-N |
M.W : | 154.56 | Pubchem ID : | 18388392 |
Synonyms : |
|
Num. heavy atoms : | 10 |
Num. arom. heavy atoms : | 9 |
Fraction Csp3 : | 0.0 |
Num. rotatable bonds : | 0 |
Num. H-bond acceptors : | 3.0 |
Num. H-bond donors : | 0.0 |
Molar Refractivity : | 35.79 |
TPSA : | 43.08 Ų |
GI absorption : | High |
BBB permeant : | Yes |
P-gp substrate : | No |
CYP1A2 inhibitor : | Yes |
CYP2C19 inhibitor : | No |
CYP2C9 inhibitor : | No |
CYP2D6 inhibitor : | No |
CYP3A4 inhibitor : | No |
Log Kp (skin permeation) : | -6.79 cm/s |
Log Po/w (iLOGP) : | 1.46 |
Log Po/w (XLOGP3) : | 0.64 |
Log Po/w (WLOGP) : | 0.78 |
Log Po/w (MLOGP) : | 0.39 |
Log Po/w (SILICOS-IT) : | 0.74 |
Consensus Log Po/w : | 0.8 |
Lipinski : | 0.0 |
Ghose : | None |
Veber : | 0.0 |
Egan : | 0.0 |
Muegge : | 1.0 |
Bioavailability Score : | 0.55 |
Log S (ESOL) : | -1.87 |
Solubility : | 2.1 mg/ml ; 0.0136 mol/l |
Class : | Very soluble |
Log S (Ali) : | -1.12 |
Solubility : | 11.7 mg/ml ; 0.0759 mol/l |
Class : | Very soluble |
Log S (SILICOS-IT) : | -1.94 |
Solubility : | 1.77 mg/ml ; 0.0115 mol/l |
Class : | Soluble |
PAINS : | 0.0 alert |
Brenk : | 0.0 alert |
Leadlikeness : | 1.0 |
Synthetic accessibility : | 2.11 |
Signal Word: | Warning | Class: | N/A |
Precautionary Statements: | P261-P305+P351+P338 | UN#: | N/A |
Hazard Statements: | H302-H315-H319-H335 | Packing Group: | N/A |
GHS Pictogram: |
* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
36% | at 120℃; for 6 h; | A mixture of the above foam (120 mg, 0.9 mmol) and POCl3 (5 mL) was heated to 120° C. for 6 h and then concentrated in vacuo. The residue was diluted with EtOAc and washed with saturated aqueous NaHCO3. The organic layer was dried (Na2SO4), filtered and concentrated in vacuo to give the desired compound as tan solid (50 mg, 36percent yield, which was used directly for the next step). MS: (ES) m/z 155.0 (M+H+). |
[ 1206825-03-7 ]
4-Chloroimidazo[2,1-f][1,2,4]triazine
Similarity: 0.92
[ 69214-33-1 ]
8-Chloroimidazo[1,2-a]pyrazine
Similarity: 0.60
[ 143591-61-1 ]
3-Bromo-8-chloroimidazo[1,2-a]pyrazine
Similarity: 0.56
[ 54126-45-3 ]
3-Chloro-N,N-dimethylpyrazin-2-amine
Similarity: 0.56
[ 1208083-37-7 ]
6-Bromo-8-chloroimidazo[1,2-a]pyrazine
Similarity: 0.55
[ 1206825-03-7 ]
4-Chloroimidazo[2,1-f][1,2,4]triazine
Similarity: 0.92
[ 399-66-6 ]
[1,2,4]Triazolo[1,5-a]pyrazine
Similarity: 0.80
[ 88002-33-9 ]
[1,2,4]Triazolo[1,5-a]pyrazin-2-amine
Similarity: 0.73
[ 944709-42-6 ]
6,8-Dibromo-[1,2,4]triazolo[1,5-a]pyrazine
Similarity: 0.61
[ 69214-33-1 ]
8-Chloroimidazo[1,2-a]pyrazine
Similarity: 0.60